Citronellyl anthranilate
|
Basic information |
| Metabolite name | Citronellyl anthranilate |
 | HMDB0032208 |
 |
C00108 |
 |
109467 |
| Synonyms | anthranilate; |
| No. of studies | 6 |
|
Basic information |
| Metabolite name | Citronellyl anthranilate |
| HMDB0032208 |
|
C00108 |
|
109467 |
| Synonyms | anthranilate; |
| No. of studies | 6 |
|
Relationship between Citronellyl anthranilate and depression (count: 6) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M147 | Type2 | FSL acute vortioxetine group vs. FSL acute control group | Plasma | Sprague-Dawley rat | Up |
| Study M147 | Type2 | FSL acute fluoxetine group vs. FSL acute control group | Plasma | Sprague-Dawley rat | Up |
| Study M147 | Type2 | FSL acute ketamine group vs. FSL acute control group | Plasma | Sprague-Dawley rat | Up |
| Study M151 | Type1 | Female FSL group vs. Female FRL group | Brain | Sprague-Dawley rat | Down |
| Study M151 | Type1 | Female FSL group vs. Female FRL group | Plasma | Sprague-Dawley rat | Down |
| Study M151 | Type1 | Male FSL group vs. Male FRL group | Plasma | Sprague-Dawley rat | Down |
| Study M482 | Type4 | ketamine-treated depression group responder vs. non-responder | Plasma | Human | Up |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Serum | C57BL/6 J mouse | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |